[The FDA] “has shifted the approval standards based on flawed, indirect data analyses, [this is] not only bad policy for patients, but also for innovation.”
Joseph Kennedy, general counsel, Amarin Corp. plc, during a conference call on the FDA’s refusal to go back on its withdrawal of the special protocol assessment deal for the trial known as ANCHOR on the triglyceride-lowering therapy Vascepa

“We had a very, very successful J.P. Morgan conference presentation and set of meetings, and both existing and potential new shareholders expressed tremendous interest in the company. I think investors are tired of looking at companies with one-offs.”
Howard W. Robin, CEO, Nektar Therapeutics Inc.

“I’m really encouraged about this work. Genetic studies are moving to the next stage, understanding more of the architecture and the foundation of the disease. That the foundation is bigger and wider than we thought – that’s really OK.”
Pamela Sklar, chief of the division of psychiatric genomics, Mount Sinai School of Medicine, on new published insights into the genetic and neural mechanisms that underlie schizophrenia